Dr. Hannestad has 25 years of experience in the field of neuroscience at both academic and biopharmaceutical organizations with a special emphasis on translational medicine and early clinical development in neurodegeneration. Dr. Hannestad is currently Chief Medical Officer at Gain Therapeutics, and previously held clinical development positions at Tranquis Therapeutics, Capacity Bio, Alkahest, Denali Therapeutics, UCB and BMS. He has worked on multiple Parkinson’s programs, including GBA, LRRK2, adenosine 2A, and alpha-synuclein. He received his MD from the University of Oviedo and a PhD from the University of Messina, and completed residency training in internal medicine and psychiatry at Duke University and Yale University.